Search Medical Condition
Please enter condition
Please choose location from dropdown

Darien, Connecticut Clinical Trials

A listing of Darien, Connecticut clinical trials actively recruiting patient volunteers.

RESULTS

Found (120) clinical trials

Revolution Peripheral Atherectomy System for Lower Extremity Peripheral Arterial Revascularization

This study intends to enroll up to 121 subjects at up to 18 investigational sites in the United States. This is a single-arm study of the Revolution Peripheral Atherectomy System in subjects with peripheral arterial disease (PAD). The primary safety endpoint is freedom from 30-day Major Adverse Events (MAE), defined ...

Phase N/A

0.75 miles

Learn More »

A Multicenter Study to Evaluate a Borrelia Diagnostic Test in Subjects With Early Stage or Late Stage Lyme Disease

This study will evaluate Advanced Laboratory Services Borrelia diagnostic test by culturing Borrelia spirochetes from human serum in subjects with early or late Lyme disease. This is an 8 month study. Subjects entering the study will have two blood samples collected one month apart if they have early Lyme disease ...

Phase N/A

0.75 miles

Learn More »

Treatment of Chronic Deep Vein Thrombosis (DVT) and Post-Thrombotic Syndrome (PTS) With the EkoSonic Endovascular System

The study is designed to evaluate the safety and efficacy of ultrasound accelerated thrombolysis using the EkoSonic® Endovascular System with standard infusion of a thrombolytic drug for PTS and chronic DVT. Clinical effectiveness will be evaluated using a standard measure of severity of post-thrombotic syndrome over a year.

Phase N/A

0.75 miles

Learn More »

Cook Enforcer Post-Market Study

The purpose of this study is to evaluate the performance of the Cook Advance Enforcer 35 Focal-Force PTA Balloon Catheter (or Enforcer balloon) in treating narrowed blood vessels compared to treatment with a conventional angioplasty balloon.

Phase N/A

0.75 miles

Learn More »

Effect of VarIthena on Wound Healing in VLU

This 12 month, multicenter, open-label registry is designed to collect treatment and outcome data related to subjects treated with Varithena for GSV system and/or AASV incompetence resulting in VLU. Subjects are treated per Investigator's SoC and in accordance with the FPI and IFU. For subjects with healed ulcers during the ...

Phase N/A

0.75 miles

Learn More »

A Randomized Double-blind Controlled Study Comparing LCZ696 to Medical Therapy for Comorbidities in HFpEF Patients

The purpose of this study is to demonstrate the superiority of LCZ696 over individualized medical therapy for comorbidities in reducing N-terminal pro-brain natriuretic peptide (NT-proBNP) and improving HF symptoms and functional capacity in patients with heart failure with preserved ejection fraction (HFpEF).

Phase

3.08 miles

Learn More »

Study to Evaluate the Effectiveness and Safety of Ocrelizumab in Participants With Early Stage Relapsing Remitting Multiple Sclerosis (RRMS)

This is a prospective, multicenter, open-label, single-arm, phase 3b study which evaluates effectiveness and safety of ocrelizumab in participants with early stage RRMS. The study will consist of an open-label treatment period of 192 weeks and follow-up period of at least 48 weeks.

Phase

3.08 miles

Learn More »

A Tolerability Study of ALKS 8700 in Subjects With Relapsing Remitting Multiple Sclerosis (RRMS) EVOLVE-MS-2

This study will assess the gastrointestinal (GI) tolerability of ALKS 8700 in adult subjects with RRMS

Phase

3.08 miles

Learn More »

A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Participants With Psoriatic Arthritis Who Have an Inadequate Response to at Least One Non-Biologic Disease Modifying Anti-Rheumatic Drug

This is a Phase 3 multicenter study that includes two periods. Period 1 is designed to compare the safety, tolerability, and efficacy of ABT-494 Dose A once daily (QD) and Dose B QD versus placebo and versus adalimumab every other week (eow) in participants with moderately to severely active Psoriatic ...

Phase

3.08 miles

Learn More »

A Study of Crenezumab Versus Placebo to Evaluate the Efficacy and Safety in Participants With Prodromal to Mild Alzheimer's Disease (AD)

This randomized, double-blind, placebo-controlled, parallel-group study will evaluate the efficacy and safety of crenezumab versus placebo in participants with prodromal to mild AD. Participants will be randomized 1:1 to receive either intravenous (IV) infusion of crenezumab or placebo every 4 weeks (q4w) for 100 weeks. The primary efficacy assessment will ...

Phase

3.08 miles

Learn More »